Search Results
Nov 12, 2025, 07:00 ET Grounded Lithium Reports Third Quarter 2025 Financial Results and Project Update
Denison Mines Corp ("Denison"), continues to progress the various technical studies necessary for the completion of the pre-feasibility study ("PFS"). Areas of focus include extensive engineering analysis in cost minimization for lithium extraction from the brine to produce a final lithium hydroxide
More news about: Grounded Lithium Corp.
Nov 11, 2025, 08:58 ET iLeukon Therapeutics Presents Phase I Data for ILKN421H at SITC 2025
patients). When analyzed by PD-L1 status, ORR was 87% in PD-L1–positive patients and 60% in PD-L1–negative patients. Median progression-free survival (PFS) has not yet been reached and is projected to exceed 12 months. In the post–immunotherapy (post-IO) NSCLC cohort (n=3), ILKN421H combined with pembrolizumab
More news about: iLeukon Therapeutics
Nov 10, 2025, 07:30 ET ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
with an overall response rate (ORR) of 98.2%, a complete response rate (CR) of 83.6%. After median follow-up of 28 months, median PFS was not reached, and the 12-month PFS was 93.9%. Safety was consistent with the known profile of ZYNLONTA. The trial has been expanded to enroll 100 patients, and the Company
More news about: ADC Therapeutics SA
Nov 10, 2025, 07:00 ET MAYFAIR PROVIDES FENN-GIB PROJECT UPDATE
Geotechnical Site Investigations for the tailing storage facility and a progress update on the Pre-Feasibility Study ("PFS") work. The Company's upcoming PFS will be based on the recently updated NI 43-101 Mineral Resource Estimate ("MRE") for the Fenn-Gib Project (see
More news about: Mayfair Gold Corp.
Nov 09, 2025, 20:55 ET Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
5 mg/kg groups. Median duration of response (DOR) was 9.3 months and 8.7 months in the 4 mg/kg and 5 mg/kg groups. Median progression free survival (PFS) was 6.0 months and 7.3 months in the 4 mg/kg and 5 mg/kg groups. Grade ≥3 treatment-related AEs (TRAEs) occurred in 59 patients
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 07, 2025, 11:30 ET Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74
statistically significant benefits in both Progression-Free Survival (PFS) and Overall Survival (OS). This final OS analysis, the first from a Phase III trial of ivonescimab, confirms the breakthrough value of ivonescimab-based therapy in improving both PFS and OS. Historically, cancer immunotherapies have largely
More news about: Akeso, Inc.
Nov 06, 2025, 20:00 ET Denison Reports Financial and Operational Results for Q3 2025, Including First Production from McClean North Uranium Mine
feasibility study was completed for the Phoenix deposit as an ISR mining operation, and an update to the previously prepared 2018 Pre-Feasibility Study ('PFS') was completed for Wheeler River's Gryphon deposit as a conventional underground mining operation. Based on the respective studies, both deposits have
More news about: Denison Mines Corp.
Nov 06, 2025, 18:44 ET Wheaton Precious Metals Announces Record Revenue, Earnings and Cash Flow for the First Nine Months of 2025
as a large-scale, long-life open pit gold project with robust economics. Based on the results of the PEA, Aris has initiated a Prefeasibility Study ("PFS"), targeted for completion in 2026, with the objective of advancing the project toward construction.
More news about: Wheaton Precious Metals Corp.
Nov 06, 2025, 17:07 ET DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
progression-free survival (PFS), defined as progression to active multiple myeloma (MM) as assessed by an independent review committee, according to IMWG diagnostic criteria for MM (SLiM-CRAB), or death. Major secondary endpoints included overall response rate, PFS on first-line MM treatment (PFS2), and overall survival.
More news about: Johnson & Johnson
Nov 06, 2025, 08:00 ET OncoHost Wins 'Proteomics Innovation of the Year' at the BioTech Breakthrough Awards
of proteins are profiled and analyzed with proprietary AI models, generating patient-specific predictive scores for both progression-free survival (PFS) and overall survival (OS). The PROphet® proteomic signature has also demonstrated predictive value across melanoma, renal cell carcinoma (RCC), HPV-associated
More news about: OncoHost
Nov 06, 2025, 07:00 ET Mark Cuban Cost Plus Drug Company Expands Access with Addition of Starjemza® (ustekinumab-hmny) to Give Patients More Power Over Prescription Costs
Starjemza® will be listed at a starting price of $345 per quarter (plus shipping) for the 90 mg/mL pre-filled syringe (PFS). Additional configurations, including the 45 mg/mL and 130 mg/mL PFS, will also be offered and priced in accordance with the company's transparent cost-plus model.
More news about: Mark Cuban Cost Plus Drug Company
Nov 05, 2025, 16:05 ET Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
ES-SCLC based on positive data from the Phase 3 IMforte trial. Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 4Q25; updated intent-to-treat population for PFS to include all patients enrolled in the trial. Narrowed 2025 total revenue
More news about: Jazz Pharmaceuticals plc
Nov 05, 2025, 16:05 ET Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
ES-SCLC based on positive data from the Phase 3 IMforte trial. Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 4Q25; updated intent-to-treat population for PFS to include all patients enrolled in the trial. Narrowed 2025 total revenue
More news about: Jazz Pharmaceuticals plc
Nov 04, 2025, 09:01 ET AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
high-plex imaging, histopathology, and clinical outcome data to identify distinct immune cell interactions that correlate with progression-free survival (PFS), overall survival (OS), and clinical benefit across three treatment arms incorporating Immune Checkpoint Blockade (ICB).
More news about: Bio-Techne Corporation
Nov 04, 2025, 08:32 ET iLeukon Receives FDA Clearance of IND Application for A Phase II Study of mRNA-based non-alpha IL-2 variant, ILKN421H, in Advanced Non-Small Cell Lung Cancer (NSCLC)
first-line NSCLC, achieved a confirmed objective response rate (ORR) of 80% (n=16/20) regardless of PD-L1 expression, with median progression-free survival (PFS) not yet reached and projected to exceed 12 months. The summary of this Phase I study was selected as an oral presentation at the upcoming SITC Annual
More news about: iLeukon Therapeutics
Nov 04, 2025, 07:30 ET Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
Clinical rationale for combination supported by a study that showed EBRT or external-beam radiotherapy + osimertinib improved PFS to 32.2 months vs. 20 months with osimertinib alone (Sampath et al.1, Lancet eClinicalMedicine, 2025). ATNM-400 has the potential to
More news about: Actinium Pharmaceuticals, Inc.
Nov 04, 2025, 06:00 ET IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM) to report median PFS data by year-end 2025 to 1Q 2026; on track to complete enrollment by year-end 21.1 month median OS and 7.0 month median PFS reported from single-arm Phase 2 trial (OptimUM-01) evaluating the darovasertib/crizotinib
More news about: IDEAYA Biosciences, Inc.
Nov 03, 2025, 19:06 ET Energy Fuels Announces Q3-2025 Results
50,000 tonnes per annum ("tpa") of monazite, producing approximately 5,000 tpa of NdPr, 150 to 225 tpa of Dy, and 50 to 75 tpa of Tb. The Mill PFS referenced above can be viewed on the Company's website,
More news about: Energy Fuels Inc.
Nov 03, 2025, 08:00 ET Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology
Median progression-free survival (PFS) improved with VORANIGO (not estimable [NE] [95% CI, 22.1-NE]) compared to placebo (11.4 [95% CI, 11.1-13.9] months), with the hazard ratio (HR) continuing to favor VORANIGO (HR, 0.35 [95% CI, 0.25-0.49]; p<0.0001*). PFS was the primary endpoint of the trial.
More news about: Servier Pharmaceuticals
Nov 03, 2025, 07:15 ET ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025
consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential
More news about: ADC Therapeutics SA
Nov 02, 2025, 23:12 ET Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer
first final OS analysis in a Phase III trial of ivonescimab, these results reaffirm the agent's groundbreaking value in both progression-free survival (PFS) and overall survival for patients. Moreover, a head-to-head Phase III trial comparing ivonescimab plus chemotherapy to tislelizumab plus chemotherapy
More news about: Akeso, Inc.
Oct 30, 2025, 10:59 ET First Dual-Positive Immunotherapy with PFS and OS Benefit in EGFR+ NSCLC After EGFR-TKI Progression: Ivonescimab Final OS Analysis from HARMONi-A to Be Presented at SITC 2025
EGFR-TKI-resistant, EGFR-mutated non-squamous NSCLC to show statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS). This marks ivonescimab's first final OS analysis in a Phase III trial and confirms its groundbreaking survival benefit for
More news about: Akeso, Inc.
Oct 30, 2025, 08:00 ET ARIS MINING ANNOUNCES APPOINTMENT OF BRIGITTE BAPTISTE TO THE BOARD
Marmato Complex, expected to start ramping up production in H2 2026. In addition, Aris Mining operates the 51% owned Soto Norte joint venture, where a PFS study is complete on a new, smaller scale development plan which confirms Soto Norte as a high-quality, long-life project with robust economics and industry-leading
More news about: Aris Mining Corporation
Oct 30, 2025, 07:00 ET Hot Chili Quarterly Report Period Ending 30 September, 2025
and exclusions. The PFS Technical Report is intended to be read as a whole, and sections should not be read or relied upon out of context. The technical information in this report is subject to the assumptions and qualifications to be contained in the PFS Technical Report. The PFS Technical Report replaces
More news about: Hot Chili Limited
Oct 29, 2025, 17:30 ET ARIS MINING REPORTS Q3 2025 RESULTS
Prefeasibility Study (PFS) completed in September 2025, demonstrating robust economics with, on a 100% basis, after-tax NPV5% of $2.7 billion, IRR of 35%, and 2.3-year
More news about: Aris Mining Corporation